Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device

Degenerative Disc Disease Clinical Trial

— FLXFit  

Official title:

Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02805985
• Other study ID #: FLXFit
• Status: Not yet recruiting
• Phase: N/A
• First received: May 25, 2016
• Last updated: January 23, 2017
• Start date: October 2016
• Est. completion date: June 2018

Study information

• Verified date: January 2017
• Source: Expanding Orthopedics Ltd.
• Contact: Kern Singh, MD
• Phone: 312-432-2373
• Email: kern.singh[@]rushortho.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a post-market clinical follow-up study. A post-market, prospective clinical trial will be conducted. The data collected from this study will serve the purpose of confirming safety and performance of the FLXfit™ implant.

Description:

As detailed by Expanding Orthopedics Inc., the FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.

The FLXfit™ is a unique titanium cage which articulates laterally as well as expands in height. This enables larger footprint support as well as restoration of disc height and lordotic angle correction. A bullet-nose design facilitates self-distraction and ease of insertion. The open architecture of the device allows it to be packed with autogenous bone graft.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: June 2018
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Adult (18-70 y/o)

• Male or Female

• With the following conditions of the lumbar spine as confirmed by advanced imaging (CT or MRI), who is a candidate for primary spinal fusion procedure according to acceptable criteria for such medical conditions:

• Degenerative disc disease with up to Grade I spondylolisthesis

• Spondylolisthesis

• Failure of at least 6-months conservative treatment

• BMI < 40

• Patient to approve no pregnancy during the 24 months of study and no participation in other studies in parallel to this one

• Ability to read, understand, and sign informed consent

Exclusion Criteria:

• Infection, local to the operative site

• Signs of local inflammation

• Fever or leukocytosis

• Pregnancy

• Significant mental disorder or condition that could compromise the patient's ability to remember and comply with preoperative and postoperative instructions (e.g. current treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's disease, traumatic head injury)

• Prior surgical procedure (with the exception of decompression only procedure) at the index level(s) using the desired operative approach

• Prior fusion procedure at an adjacent level

• Any other condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors or congenital abnormalities, fracture local to the operating site, elevation of segmentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count

• Neuromuscular disorder that would engender unacceptable risk of instability, implant fixation failure, or complications in postoperative care

• Active local infection in or near the operative region

• Active systemic infection and/or disease

• Severe osteoporosis or insufficient bone density, which in the medical opinion of the physician precludes surgery or contraindicates instrumentation

• Endocrine or metabolic disorders known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, hypothyroidism)

• Systemic disease that requires the chronic administration of nonsteroidal anti-inflammatory or steroidal drugs

• Suspected or documented allergy or intolerance to implant's materials

• Symptomatic cardiac disease

• Patient unwilling to cooperate with postoperative instructions.

• Any case where the implant components selected for use would be too large or too small to achieve a successful result.

• Patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality.

• Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance.

• Prior fusion at the level to be treated.

• Back VAS < 4/10

Related Conditions & MeSH terms

• Degenerative Disc Disease
• Intervertebral Disc Degeneration
• Retrolisthesis
• Spondylolisthesis

Intervention

Device:
• FLXfit™ TLIF Interbody Fusion Device
The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.

Locations

Country	Name	City	State
United States	Rush University Medical Center; Department of Orthopedic Surgery	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Expanding Orthopedics Ltd.	Rush University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety/Adverse Events	All adverse events will be assessed by incidence and time to resolution of postoperative device-related complications and serious adverse events/incidence and time to reoperation/incidence and time to revision. All perioperative adverse events will be noted. Information will be obtained from the operative note regarding blood loos, length of surgery, procedural details and complications. Postoperative events including nausea, vomiting, wound complications, thromboembolic events will be assessed.	Up to 24 months
Secondary	Disability	Obtaining improvement in Oswestry Disability Index (ODI) disease-specific questionnaire up to 24 months following the procedure, as compared to patient's baseline. Mean change in score of the ODI from baseline to 24 months postoperatively	24 months
Secondary	Change in Disability	Obtaining improvement in Oswestry Disability Index (ODI) disease-specific questionnaire up to 24 months following the procedure, as compared to patient's baseline. Mean change in score of the ODI from baseline to 24 months postoperatively	Up to 24 months
Secondary	Pain	Obtaining improvement in Visual Analogue Scale (VAS) Back and Leg pain scores up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the VAS from baseline to 24 months postoperatively	24 months
Secondary	Change in Pain	Obtaining improvement in Visual Analogue Scale (VAS) Back and Leg pain scores up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the VAS from baseline to 24 months postoperatively	Up to 24 months
Secondary	Health-Related Quality of Life Questionnaire	Obtaining improvement in Short Form-12 health survey up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the SF-12 from baseline to 24 months postoperatively	24 months
Secondary	Change in Health-Related Quality of Life Questionnaire	Obtaining improvement in Short Form-12 health survey up to 24 months following the procedure as compared to patient's baseline. Mean change in score of the SF-12 from baseline to 24 months postoperatively	Up to 24 months
Secondary	Arthrodesis (Fusion)	CT based fusion assessment at 6 months, 12 months, and 24 months	6 months, 12 months, 24 months
Secondary	Radiographic Analysis (Global Lumbar Lordosis)	Immediate Postoperative, and at the 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits assessing global lumbar lordosis (LL) at the level treated with the FLXfit device.	Immediate Postoperative, 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits
Secondary	Radiographic Analysis (Segmental Lumbar Lordosis)	Immediate Postoperative, and at the 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits assessing segmental lumbar lordosis (LL) at the level treated with the FLXfit device.	Immediate Postoperative, 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits